|
|
|
|
|
|
|
|
OncologySTAT: Dr. Cervantes, what were the most important studies in ovarian cancer that were presented at this year’s ESMO Congress?
Dr. Andres Cervantes: For me, the most important study was the ICON7 trial, which was presented during the presidential session of the ESMO Congress.1 It was a very important presentation because the paper is the result of a randomized phase III trial by a large cooperative group. The study was done within the Gynaecologic Cancer InterGroup, with an effort of several other cooperative groups, including the British MRC/NCRI, the leading group. However, also involved were the German AGO-OVAR, the Australian and New Zealand ANZGOG, the Spanish group for research in gynecologic and ovarian cancer, GEICO, the French GINECO, the Scandinavian group NSGO, and the National Cancer Institute of Canada, NCIC....cont'd
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.